Webinar about ATMPs - organized by Lif

ATMP-frokost-webinar 2

On Thursday, 10 September 2026 from 12:00 to 13:00 hrs., Lif invites you to another ATMP lunch webinar, where you can learn more about the approval of ATMPs.

Spend your lunch break with leading regulatory experts and learn more about the process of obtaining approval for ATMPs.

First, Martin B. Oleksiewicz, Senior Advisor at the Danish Medicines Agency and the Danish member of EMA’s Committee for Advanced Therapies (CAT), will provide insight into how the authorities approve ATMPs and how the approval process for ATMPs differs from that for other conventional medicines. What specific considerations do authorities and businesses need to consider when it comes to ATMPs?

Next, Lucas Andre Dirson, Global Program Regulatory Associate Director at Novartis, will provide insight into how businesses approach the approval process for an ATMP and how the regulatory process for ATMPs differs from that for other (conventional) drugs.

Following the presentations, there will be an opportunity to ask questions and share your own experiences. The scene is set for an intense lunch, with plenty to digest afterward.

You can register for the webinar here: https://www.lyyti.in/ATMPfrokostwebinar_2.

Please register no later than Monday, 7 September 2026. You will receive an Outlook invitation with a Teams link the day before the webinar.

Please note that the webinar will be in English and it will be recorded. Webinar attendance is free.

This is the second webinar in a series of lunch webinars in 2026 in which Lif aims to highlight the industry’s contribution to the development, production, regulatory approval, and practical application of ATMPs. The goal is to provide insight into the steps, considerations, opportunities, and barriers that shape the pharmaceutical industry’s practical work in bringing new innovative ATMPs to Danish patients.